8-K: Invivyd Inc. Provides Corporate Update, Highlights Progress in COVID-19 Antibody Development

Invivyd Inc. released an updated corporate presentation detailing the ongoing launch of their COVID-19 preventative antibody, PEMGARDA, and progress on their next-generation antibody, VYD2311.

Summary

• Invivyd is focused on developing monoclonal antibodies (mAbs) to combat COVID-19, particularly for immunocompromised individuals.
• The company's lead product, PEMGARDA, is authorized for pre-exposure prophylaxis (PrEP) of COVID-19 in certain immunocompromised adults and adolescents.
• Invivyd has submitted an EUA amendment request to the FDA for PEMGARDA to be used in the treatment of COVID-19 in certain immunocompromised patients.
• The company is developing a next-generation mAb, VYD2311, which has shown in vitro neutralization activity against recent COVID-19 variants.
• Invivyd has established a repeatable immunobridging pathway with the FDA for rapid development of serial mAbs.
• COVID-19 continues to be a significant health threat, with approximately one person in the U.S. dying every 8 minutes from the virus.
• The company believes that current COVID-19 vaccines are insufficient, especially for immunocompromised individuals, with vaccine effectiveness against hospitalization ranging from 7% to 42% depending on the time since the dose.
• PEMGARDA has shown an 84% reduction in the risk of symptomatic COVID-19 in an immunocompetent cohort.
• The company is seeing rapid growth in commercial coverage for PEMGARDA, including major national and regional plans.
• Invivyd is exploring potential opportunities in other viral areas such as RSV, HBV/HDV, and influenza.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on Invivyd's prospects, highlighting the potential of their platform and products to address the ongoing COVID-19 pandemic. The company's progress in commercialization and development of next-generation mAbs is encouraging. However, the document also acknowledges the risks and challenges associated with drug development and regulatory approvals.

Positives

• PEMGARDA is the first and only mAb authorized for both PrEP and treatment of COVID-19 in certain immunocompromised patients, if the treatment EUA is granted.
• The company has a proprietary platform for rapid mAb engineering and development.
• Invivyd has a general alignment with the FDA on a repeatable EUA pathway for serial mAbs.
• The company is experiencing rapid growth in commercial coverage for PEMGARDA.
• VYD2311 shows promise with improved biophysical properties and in vitro neutralization activity against recent COVID-19 variants.
• The management team has relevant expertise and a track record of success.

Negatives

• COVID-19 vaccines have limited effectiveness, especially for immunocompromised individuals.
• Current COVID-19 treatments have limitations, including drug interaction issues and potential for viral rebound.
• The company is dependent on third parties for manufacturing, labeling, packaging, storing, and distributing their product candidates.
• The EUA for PEMGARDA is subject to the FDA's declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic.
• The company faces risks related to the regulatory authorization or approval process and the potential for changes in the regulatory environment.

Risks

• The EUA for PEMGARDA could be revoked or revised by the FDA.
• The company may face challenges in maintaining and expanding sales, marketing, and distribution capabilities.
• There is a risk of changes in expected or existing competition.
• The outcome of the EUA amendment request for PEMGARDA treatment is uncertain.
• The company's ability to effectively utilize an immunobridging pathway for future EUAs is not guaranteed.
• There are risks associated with the timing, progress, and results of discovery, preclinical, and clinical development activities.
• Unexpected safety or efficacy data could arise during preclinical studies or clinical trials.
• The company's ability to maintain a continued acceptable safety, tolerability, and efficacy profile of any product candidate following regulatory authorization or approval is not guaranteed.
• There is a risk that results of nonclinical studies or clinical trials may not be predictive of future results.
• The company relies on third parties for virus assay creation, product candidate testing, and clinical trials.
• There is potential variability in neutralizing activity of product candidates tested in different assays.
• The company faces the risk that pemivibart, VYD2311, or any other product candidate may not be able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants.
• The company is dependent on third parties to manufacture, label, package, store, and distribute clinical and commercial supplies of product candidates.
• The company may not be able to provide sufficient commercial supply of PEMGARDA to meet market demand.
• The company may not be able to obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA or any other product candidate.
• The company may not be able to achieve high potency and/or variation resistance with future product pipeline.
• The company faces the risk of legal proceedings or investigations.
• The company's ability to continue as a going concern is dependent on adequate funding.
• The company may not have adequate funding to meet future operating expenses and capital expenditure requirements.

Future Outlook

Invivyd aims to be perpetually ready for COVID-19 and pandemic threats by continually staying ahead of viral evolution with their rapid mAb engineering platform. They plan to expand the use of PEMGARDA to treatment if the EUA amendment is approved and continue development of VYD2311. They are also exploring opportunities in other viral areas.

Management Comments

• The company believes COVID-19 vaccines are insufficient for real protection, especially for immunocompromised people.
• Invivyd sees the COVID-19 standard of care as sub-standard, creating immense opportunity for monoclonal antibodies.
• The company is working to raise the bar on the standard of care by continually staying ahead of viral evolution.
• Invivyd aims to be the virology mAb company.

Industry Context

The document highlights the ongoing need for effective COVID-19 treatments and preventatives, particularly for immunocompromised individuals, as the virus continues to evolve. It positions Invivyd as a leader in developing next-generation mAbs to address the limitations of current vaccines and treatments. The company is attempting to address the issue of viral evolution which has rendered previous monoclonal antibody treatments ineffective.

Comparison to Industry Standards

• The document compares PEMGARDA's 84% reduction in symptomatic COVID-19 risk to other monoclonal antibodies like Adintrevimab (71%) and Tixagevimab+cilgavimab (77%).
• The document highlights the limited effectiveness of current COVID-19 vaccines, with a maximum of 38% effectiveness against hospitalization in immunocompromised individuals, suggesting a need for alternative solutions like mAbs.
• The document notes that other mAbs have lost effectiveness due to viral evolution, positioning Invivyd's platform as a solution to this problem.
• The document references the limitations of current treatments like Paxlovid (drug interactions, rebound) and Veklury (daily infusions), highlighting the need for better options.

Stakeholder Impact

• Shareholders: The company's progress and potential for growth could positively impact shareholder value.
• Employees: The company's success could lead to job security and growth opportunities.
• Customers: Immunocompromised individuals could benefit from access to effective COVID-19 prevention and treatment options.
• Suppliers: The company's growth could lead to increased demand for their products and services.
• Creditors: The company's financial stability and growth potential could improve their creditworthiness.

Next Steps

• Continue the commercial launch of PEMGARDA for pre-exposure prophylaxis.
• Obtain EUA amendment approval for PEMGARDA for COVID-19 treatment.
• Advance the development of VYD2311 through clinical trials.
• Explore potential opportunities in other viral areas such as RSV, HBV/HDV, and influenza.

Key Dates

Keywords

COVID-19, monoclonal antibodies, PEMGARDA, VYD2311, immunocompromised, pre-exposure prophylaxis, EUA, FDA, immunobridging, viral evolution